Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.

Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klco JM, Helton NM, O'Laughlin M, Fronick CC, Fulton RS, Wilson RK, Wartman LD, Welch JS, Heath SE, Baty JD, Payton JE, Graubert TA, Link DC, Walter MJ, Westervelt P, Ley TJ, DiPersio JF.

N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777. [Epub ahead of print]

2.

Acute Myeloid Leukemia: The Good, the Bad, and the Ugly.

Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):555-573. doi: 10.1200/EDBK_199519.

3.

Mutation Clearance after Transplantation for Myelodysplastic Syndrome.

Duncavage EJ, Jacoby MA, Chang GS, Miller CA, Edwin N, Shao J, Elliott K, Robinson J, Abel H, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Brendel K, Saba R, Wartman LD, Christopher MJ, Pusic I, Welch JS, Uy GL, Link DC, DiPersio JF, Westervelt P, Ley TJ, Trinkaus K, Graubert TA, Walter MJ.

N Engl J Med. 2018 Sep 13;379(11):1028-1041. doi: 10.1056/NEJMoa1804714.

PMID:
30207916
4.

A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion.

Miller CA, Tricarico C, Skidmore ZL, Uy GL, Lee YS, Hassan A, O'Laughlin MD, Schmidt H, Tian L, Duncavage EJ, Griffith M, Griffith OL, Welch JS, Wartman LD.

Blood Adv. 2018 Jun 12;2(11):1295-1299. doi: 10.1182/bloodadvances.2017014183. No abstract available.

5.

Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow.

Bansal D, Vij K, Chang GS, Miller CA, DiPersio JF, Vij R, Heath SE, Westervelt P, Welch JS, Fehniger TA.

Haematologica. 2018 Jun;103(6):e270-e273. doi: 10.3324/haematol.2017.184168. Epub 2018 Mar 22. No abstract available.

6.

Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.

Jacoby MA, Duncavage EJ, Chang GS, Miller CA, Shao J, Elliott K, Robinson J, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Pusic I, Welch JS, Link DC, DiPersio JF, Westervelt P, Ley TJ, Graubert TA, Walter MJ.

JCI Insight. 2018 Mar 8;3(5). pii: 98962. doi: 10.1172/jci.insight.98962. [Epub ahead of print]

7.

Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.

Wong TN, Miller CA, Jotte MRM, Bagegni N, Baty JD, Schmidt AP, Cashen AF, Duncavage EJ, Helton NM, Fiala M, Fulton RS, Heath SE, Janke M, Luber K, Westervelt P, Vij R, DiPersio JF, Welch JS, Graubert TA, Walter MJ, Ley TJ, Link DC.

Nat Commun. 2018 Jan 31;9(1):455. doi: 10.1038/s41467-018-02858-0.

8.

Endogenous retinoid X receptor ligands in mouse hematopoietic cells.

Niu H, Fujiwara H, di Martino O, Hadwiger G, Frederick TE, Menéndez-Gutiérrez MP, Ricote M, Bowman GR, Welch JS.

Sci Signal. 2017 Oct 31;10(503). pii: eaan1011. doi: 10.1126/scisignal.aan1011.

9.

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.

Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS.

Cancer Med. 2017 Dec;6(12):2814-2821. doi: 10.1002/cam4.1231. Epub 2017 Oct 23.

10.

Decitabine in TP53-Mutated AML.

Welch JS, Petti AA, Ley TJ.

N Engl J Med. 2017 Feb 23;376(8):797-8. doi: 10.1056/NEJMc1616062. No abstract available.

PMID:
28225682
11.

CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.

Spencer DH, Russler-Germain DA, Ketkar S, Helton NM, Lamprecht TL, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Shinawi M, Westervelt P, Payton JE, Wartman LD, Welch JS, Wilson RK, Walter MJ, Link DC, DiPersio JF, Ley TJ.

Cell. 2017 Feb 23;168(5):801-816.e13. doi: 10.1016/j.cell.2017.01.021. Epub 2017 Feb 16.

12.

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

Duncavage EJ, Uy GL, Petti AA, Miller CA, Lee YS, Tandon B, Gao F, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Jacoby MA, Cashen AF, Wartman LD, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ, Welch JS.

Blood. 2017 Mar 9;129(10):1397-1401. doi: 10.1182/blood-2016-10-745273. Epub 2017 Jan 12. No abstract available.

13.

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ.

N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.

14.

Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy.

Uy GL, Duncavage EJ, Chang GS, Jacoby MA, Miller CA, Shao J, Heath S, Elliott K, Reineck T, Fulton RS, Fronick CC, O'Laughlin M, Ganel L, Abboud CN, Cashen AF, DiPersio JF, Wilson RK, Link DC, Welch JS, Ley TJ, Graubert TA, Westervelt P, Walter MJ.

Leukemia. 2017 Apr;31(4):872-881. doi: 10.1038/leu.2016.282. Epub 2016 Oct 14.

15.

Pathways of retinoid synthesis in mouse macrophages and bone marrow cells.

Niu H, Hadwiger G, Fujiwara H, Welch JS.

J Leukoc Biol. 2016 Jun;99(6):797-810. doi: 10.1189/jlb.2HI0415-146RR. Epub 2016 Jan 14.

16.

Patterns and functional implications of rare germline variants across 12 cancer types.

Lu C, Xie M, Wendl MC, Wang J, McLellan MD, Leiserson MD, Huang KL, Wyczalkowski MA, Jayasinghe R, Banerjee T, Ning J, Tripathi P, Zhang Q, Niu B, Ye K, Schmidt HK, Fulton RS, McMichael JF, Batra P, Kandoth C, Bharadwaj M, Koboldt DC, Miller CA, Kanchi KL, Eldred JM, Larson DE, Welch JS, You M, Ozenberger BA, Govindan R, Walter MJ, Ellis MJ, Mardis ER, Graubert TA, Dipersio JF, Ley TJ, Wilson RK, Goodfellow PJ, Raphael BJ, Chen F, Johnson KJ, Parvin JD, Ding L.

Nat Commun. 2015 Dec 22;6:10086. doi: 10.1038/ncomms10086.

17.

Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.

Wong TN, Miller CA, Klco JM, Petti A, Demeter R, Helton NM, Li T, Fulton RS, Heath SE, Mardis ER, Westervelt P, DiPersio JF, Walter MJ, Welch JS, Graubert TA, Wilson RK, Ley TJ, Link DC.

Blood. 2016 Feb 18;127(7):893-7. doi: 10.1182/blood-2015-10-677021. Epub 2015 Dec 2.

18.

Hand-foot syndrome following decitabine.

Ali AM, Jacoby M, Welch JS.

Ann Hematol. 2016 Feb;95(3):535-6. doi: 10.1007/s00277-015-2546-1. Epub 2015 Nov 6. No abstract available.

19.

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.

Klco JM, Miller CA, Griffith M, Petti A, Spencer DH, Ketkar-Kulkarni S, Wartman LD, Christopher M, Lamprecht TL, Helton NM, Duncavage EJ, Payton JE, Baty J, Heath SE, Griffith OL, Shen D, Hundal J, Chang GS, Fulton R, O'Laughlin M, Fronick C, Magrini V, Demeter RT, Larson DE, Kulkarni S, Ozenberger BA, Welch JS, Walter MJ, Graubert TA, Westervelt P, Radich JP, Link DC, Mardis ER, DiPersio JF, Wilson RK, Ley TJ.

JAMA. 2015 Aug 25;314(8):811-22. doi: 10.1001/jama.2015.9643.

20.

Absence of natural intracellular retinoids in mouse bone marrow cells and implications for PML-RARA transformation.

Niu H, Chacko J, Hadwiger G, Welch JS.

Blood Cancer J. 2015 Feb 27;5:e284. doi: 10.1038/bcj.2015.2. No abstract available.

21.

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.

Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, Lamprecht TL, Shen D, Hundal J, Fulton RS, Heath S, Baty JD, Klco JM, Ding L, Mardis ER, Westervelt P, DiPersio JF, Walter MJ, Graubert TA, Ley TJ, Druley T, Link DC, Wilson RK.

Nature. 2015 Feb 26;518(7540):552-555. doi: 10.1038/nature13968. Epub 2014 Dec 8.

22.

Age-related mutations associated with clonal hematopoietic expansion and malignancies.

Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt HK, Yellapantula V, Miller CA, Ozenberger BA, Welch JS, Link DC, Walter MJ, Mardis ER, Dipersio JF, Chen F, Wilson RK, Ley TJ, Ding L.

Nat Med. 2014 Dec;20(12):1472-8. doi: 10.1038/nm.3733. Epub 2014 Oct 19.

23.

Mutation position within evolutionary subclonal architecture in AML.

Welch JS.

Semin Hematol. 2014 Oct;51(4):273-81. doi: 10.1053/j.seminhematol.2014.08.004. Epub 2014 Aug 7.

PMID:
25311740
24.

SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution.

Miller CA, White BS, Dees ND, Griffith M, Welch JS, Griffith OL, Vij R, Tomasson MH, Graubert TA, Walter MJ, Ellis MJ, Schierding W, DiPersio JF, Ley TJ, Mardis ER, Wilson RK, Ding L.

PLoS Comput Biol. 2014 Aug 7;10(8):e1003665. doi: 10.1371/journal.pcbi.1003665. eCollection 2014 Aug.

25.

A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.

Welch JS, Niu H, Uy GL, Westervelt P, Abboud CN, Vij R, Stockerl-Goldstein KE, Jacoby M, Pusic I, Schroeder MA, Dipersio JF, Cashen AF.

Am J Hematol. 2014 Aug;89(8):E103-8. doi: 10.1002/ajh.23735. Epub 2014 Apr 28.

26.

Mutational landscape and significance across 12 major cancer types.

Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MDM, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L.

Nature. 2013 Oct 17;502(7471):333-339. doi: 10.1038/nature12634.

27.

Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice.

Wartman LD, Welch JS, Uy GL, Klco JM, Lamprecht T, Varghese N, Nagarajan R, Ley TJ.

PLoS One. 2012;7(10):e46529. doi: 10.1371/journal.pone.0046529. Epub 2012 Oct 8.

28.

Solid, low-attenuation splenic lesions on computed tomography in patients with indolent lymphoma often signal transformation: a series of ten patients.

Welch JS, Foyil KV, Powers ML, Middleton WD, Bartlett NL.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):452-4. doi: 10.1016/j.clml.2012.08.001. Epub 2012 Sep 14. No abstract available.

PMID:
22981965
29.

The origin and evolution of mutations in acute myeloid leukemia.

Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, Wartman LD, Lamprecht TL, Liu F, Xia J, Kandoth C, Fulton RS, McLellan MD, Dooling DJ, Wallis JW, Chen K, Harris CC, Schmidt HK, Kalicki-Veizer JM, Lu C, Zhang Q, Lin L, O'Laughlin MD, McMichael JF, Delehaunty KD, Fulton LA, Magrini VJ, McGrath SD, Demeter RT, Vickery TL, Hundal J, Cook LL, Swift GW, Reed JP, Alldredge PA, Wylie TN, Walker JR, Watson MA, Heath SE, Shannon WD, Varghese N, Nagarajan R, Payton JE, Baty JD, Kulkarni S, Klco JM, Tomasson MH, Westervelt P, Walter MJ, Graubert TA, DiPersio JF, Ding L, Mardis ER, Wilson RK.

Cell. 2012 Jul 20;150(2):264-78. doi: 10.1016/j.cell.2012.06.023.

30.

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.

Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF.

Nature. 2012 Jan 11;481(7382):506-10. doi: 10.1038/nature10738.

31.

Genomics of AML: clinical applications of next-generation sequencing.

Welch JS, Link DC.

Hematology Am Soc Hematol Educ Program. 2011;2011:30-5. doi: 10.1182/asheducation-2011.1.30. Review.

PMID:
22160009
32.

State of the art in myeloid sarcoma.

Klco JM, Welch JS, Nguyen TT, Hurley MY, Kreisel FH, Hassan A, Lind AC, Frater JL.

Int J Lab Hematol. 2011 Dec;33(6):555-65. doi: 10.1111/j.1751-553X.2011.01361.x. Epub 2011 Aug 24. Review.

PMID:
21883967
33.

Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.

Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, Cashen AF, Vij R.

Am J Hematol. 2011 Sep;86(9):796-800. doi: 10.1002/ajh.22092. Epub 2011 Aug 3. No abstract available.

34.

Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

Welch JS, Westervelt P, Ding L, Larson DE, Klco JM, Kulkarni S, Wallis J, Chen K, Payton JE, Fulton RS, Veizer J, Schmidt H, Vickery TL, Heath S, Watson MA, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Ley TJ, Wilson RK.

JAMA. 2011 Apr 20;305(15):1577-84. doi: 10.1001/jama.2011.497.

35.

Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression.

Wartman LD, Larson DE, Xiang Z, Ding L, Chen K, Lin L, Cahan P, Klco JM, Welch JS, Li C, Payton JE, Uy GL, Varghese N, Ries RE, Hoock M, Koboldt DC, McLellan MD, Schmidt H, Fulton RS, Abbott RM, Cook L, McGrath SD, Fan X, Dukes AF, Vickery T, Kalicki J, Lamprecht TL, Graubert TA, Tomasson MH, Mardis ER, Wilson RK, Ley TJ.

J Clin Invest. 2011 Apr;121(4):1445-55. doi: 10.1172/JCI45284. Epub 2011 Mar 23.

36.

PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice.

Welch JS, Yuan W, Ley TJ.

J Clin Invest. 2011 Apr;121(4):1636-45. doi: 10.1172/JCI42953.

37.

Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice.

Welch JS, Klco JM, Varghese N, Nagarajan R, Ley TJ.

Blood. 2011 Feb 24;117(8):2460-8. doi: 10.1182/blood-2010-08-300087. Epub 2010 Dec 29.

38.

Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice.

Martin MG, Welch JS, Uy GL, Fehniger TA, Kulkarni S, Duncavage EJ, Walter MJ.

Leukemia. 2010 Sep;24(9):1662-4. doi: 10.1038/leu.2010.156. Epub 2010 Jul 29. No abstract available.

39.

A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia.

Uy GL, Lane AA, Welch JS, Grieselhuber NR, Payton JE, Ley TJ.

Blood. 2010 Nov 4;116(18):3604-10. doi: 10.1182/blood-2008-11-189282. Epub 2010 Jul 20.

40.

Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.

Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, Dipersio JF, Vij R.

Am J Hematol. 2009 Nov;84(11):733-7. doi: 10.1002/ajh.21545.

41.

Cladribine in the treatment of acute myeloid leukemia: a single-institution experience.

Martin MG, Welch JS, Augustin K, Hladnik L, DiPersio JF, Abboud CN.

Clin Lymphoma Myeloma. 2009 Aug;9(4):298-301. doi: 10.3816/CLM.2009.n.058.

PMID:
19717379
42.

Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study.

Martin MG, Welch JS, Luo J, Ellis MJ, Graubert TA, Walter MJ.

Breast Cancer Res Treat. 2009 Dec;118(3):593-8. doi: 10.1007/s10549-009-0376-3. Epub 2009 Mar 26.

43.
44.

Genomics and inductive reasoning: revolution, renaissance, or rhetoric?

Welch JS, Rogler G.

Genet Med. 2003 Nov-Dec;5(6):476-8. No abstract available.

PMID:
14614401
45.

PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages.

Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK.

Proc Natl Acad Sci U S A. 2003 May 27;100(11):6712-7. Epub 2003 May 9.

46.

TH2 cytokines and allergic challenge induce Ym1 expression in macrophages by a STAT6-dependent mechanism.

Welch JS, Escoubet-Lozach L, Sykes DB, Liddiard K, Greaves DR, Glass CK.

J Biol Chem. 2002 Nov 8;277(45):42821-9. Epub 2002 Sep 4.

47.

Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray.

Napoli C, de Nigris F, Welch JS, Calara FB, Stuart RO, Glass CK, Palinski W.

Circulation. 2002 Mar 19;105(11):1360-7.

PMID:
11901049
48.
49.

15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway.

Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, Glass CK.

Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4844-9.

50.

The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function.

Ricote M, Huang JT, Welch JS, Glass CK.

J Leukoc Biol. 1999 Nov;66(5):733-9. Review.

PMID:
10577502

Supplemental Content

Loading ...
Support Center